- $641.40m
- $30.19m
- 53
- 33
- 93
- 62
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.06 | ||
| Price to Tang. Book | 1.06 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -16.43% | ||
| Return on Equity | -12.03% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | 1.1 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.
Directors
- Daniel Welch NEC (63)
- David Hung PRE (63)
- Jennifer Fox CFO (49)
- Stacy Markel SVP (56)
- Thomas Templeman SVP (61)
- Gary Hattersley CSO (54)
- Sergey Yurasov EXO (52)
- Oleg Nodelman DRC (44)
- Robert Bazemore IND (53)
- Kim Blickenstaff IND (68)
- Michelle Doig IND (47)
- Kathryn Falberg IND (60)
- W. Anthony Vernon IND (65)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- April 24th, 2020
- Public Since
- July 1st, 2020
- No. of Shareholders
- 41
- No. of Employees
- 51
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
New York Stock Exchange- Shares in Issue
- 246,692,474
- Address
- 357 Tehama Street, Floor 3, SAN FRANCISCO, 94103
- Web
- https://www.nuvationbio.com/
- Phone
- +1 4157543517
- Contact
- Joe Rayne
- Auditors
- KPMG LLP
Upcoming Events for NUVB
Q2 2024 Nuvation Bio Inc Earnings Release
Similar to NUVB
ADC Therapeutics SA
New York Stock Exchange
Alto Neuroscience
New York Stock Exchange
Annovis Bio
New York Stock Exchange
Arcus Biosciences
New York Stock Exchange
Biohaven
New York Stock Exchange
FAQ
What is the Nuvation Bio share price?
As of Today at 19:16 UTC, shares in Nuvation Bio are trading at $2.60. This share price information is delayed by 15 minutes.
How has the Nuvation Bio share price performed this year?
Shares in Nuvation Bio last closed at $2.60 and the price had moved by +52.05% over the past 365 days. In terms of relative price strength the Nuvation Bio share price has outperformed the S&P500 Index by +26.53% over the past year.
What are the analyst and broker recommendations for Nuvation Bio?
The overall consensus recommendation for Nuvation Bio is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Nuvation Bio dividend yield?
Nuvation Bio does not currently pay a dividend.
Does Nuvation Bio pay a dividend?
Nuvation Bio does not currently pay a dividend.
When does Nuvation Bio next pay dividends?
Nuvation Bio does not currently pay a dividend.
How do I buy Nuvation Bio shares?
To buy shares in Nuvation Bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Nuvation Bio?
As of the previous close price of $2.60, shares in Nuvation Bio had a market capitalisation of $641.40m.
Where are Nuvation Bio shares listed?
Here are the trading details for Nuvation Bio:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: NUVB
What kind of share is Nuvation Bio?
Based on an overall assessment of its quality, value and momentum Nuvation Bio is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Nuvation Bio share price forecast for 2024?
The analyst consensus target price for shares in Nuvation Bio is $5.90. That is 126.92% above the last closing price of $2.60.
Analysts covering Nuvation Bio currently have a consensus Earnings Per Share (EPS) forecast of -$0.35 for the next financial year.
What is the trend in the Nuvation Bio share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nuvation Bio. Over the past six months, its share price has outperformed the S&P500 Index by +88.66%.
As of the last closing price of $2.60, shares in Nuvation Bio were trading +50.17% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Nuvation Bio PE Ratio?
The Nuvation Bio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.60.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Nuvation Bio?
Nuvation Bio's management team is headed by:
- Daniel Welch - NEC
- David Hung - PRE
- Jennifer Fox - CFO
- Stacy Markel - SVP
- Thomas Templeman - SVP
- Gary Hattersley - CSO
- Sergey Yurasov - EXO
- Oleg Nodelman - DRC
- Robert Bazemore - IND
- Kim Blickenstaff - IND
- Michelle Doig - IND
- Kathryn Falberg - IND
- W. Anthony Vernon - IND